thiacyclononane | 6007-54-1

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: thiacyclononane
• 英文别名: thionane；Thionan；sulfonane
• CAS: 6007-54-1
• 化学式: C₈H₁₆S
• 分子量: 144.281
• InChiKey: JFPFLSVIMBQNLB-UHFFFAOYSA-N

物化性质

• 沸点：
  222.94°C (rough estimate)
• 密度：
  0.9449
• 保留指数：
  1139

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  thiacyclononane 在 双氧水 作用下， 生成 Thiacyclononan-1.1-dioxyd
  参考文献：
  名称：

  Thia- und Dithia-cycloalkane und die Spaltung einiger ges�ttigter Heterocyclen mit Methyljodid

  摘要：

  DOI：

  10.1007/bf00904146
• 作为产物：
  描述：

  1,8-二溴辛烷 在 aluminum oxide 、 硫化氢 作用下， 以 甲苯 为溶剂， 反应 20.0h， 以37.7%的产率得到thiacyclononane
  参考文献：
  名称：

  The macrocyclization reaction of terminal dibromoalkanes with sulfide on alumina. The use of a solid support as an alternative to the high dilution technique.

  摘要：

  DOI：

  10.1016/0040-4039(93)88023-c

文献信息

• Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
  申请人：Zhang Wei

  公开号：US20060128957A1

  公开（公告）日：2006-06-15

  The present invention includes methods and compositions for increasing the fluorous nature of an organic compound by reacting it with at least one fluorous compound to produce a fluorous tagged organic compound. The increased fluorous nature of the fluorous tagged organic compound can then be utilized to separate the fluorous organic compound from untagged reagents, reactants, catalysts and/or products derived therefrom. The resultant fluorous tagged organic compound can be subjected to subsequent chemical transformations, wherein the fluorous nature of the tagged compound is utilized to increase the ease of separation of the fluorous tagged organic compound from untagged reagents, reactants, catalysts and/or products derived therefrom, after each chemical transformation. The chemical transformations result in a second fluorous tagged organic compound wherein the fluorous nature of the second fluorous tagged organic compound can then be reduced by removing the fluorous group therefrom, thereby producing a second organic compound that may be employed as a pharmaceutical compound or intermediate, or a combinatorial library component.

  本发明涉及一种通过将有机化合物与至少一种氟碳化合物反应以产生标记有氟碳基团的有机化合物的方法和组合物。标记有氟碳基团的有机化合物的氟碳性质增强后，可以利用它将氟碳有机化合物与未标记的试剂、反应物、催化剂和/或由其衍生的产物分离开来。所得到的标记有氟碳基团的有机化合物可以进行后续的化学转化，其中使用标记化合物的氟碳性质可以增加从每个化学转化后将标记有氟碳基团的有机化合物与未标记的试剂、反应物、催化剂和/或由其衍生的产物分离的便利性。化学转化产生第二个标记有氟碳基团的有机化合物，然后可以通过去除其中的氟碳基团来降低第二个标记有氟碳基团的有机化合物的氟碳性质，从而产生可用作制药化合物或中间体，或组合化学库组分的第二个有机化合物。
• Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
  申请人：G.D. Searle & Co.

  公开号：US20020143033A1

  公开（公告）日：2002-10-03

  This invention is in the field of a combination comprising a therapeutically-effective amount of a cyclooxygenase-2 inhibitor, a 5-lipoxygenase inhibitor and an immunosuppressive drug selected from antiproliferative agents, antiinflammatory-acting compounds and inhibitors of leukocyte activation. This combination may be used, for example, to suppress the immune response associated with organ transplantation, graft versus host disease, and conditions with underlying autoimmune or inflammatory reactivities or responses.

  本发明涉及一种组合物，包括治疗有效量的环氧合酶-2抑制剂、5-脂氧合酶抑制剂和免疫抑制药物，所述免疫抑制药物选自抗增殖剂、抗炎症作用化合物和白细胞激活抑制剂。该组合物可用于抑制与器官移植、移植物抗宿主病和基于自身免疫或炎症反应的疾病相关的免疫反应。
• Hardenable dental compositions with low polymerization shrinkage
  申请人：Abuelyaman Ahmed S.

  公开号：US20090118389A1

  公开（公告）日：2009-05-07

  The present invention features a hardenable dental composition that contains: (1) at least one cyclic allylic compound having at least one sulfur atom in the ring, and (2) at least one at least one ethylenically unsaturated compound, such as a substituted (meth)acryloyl compound. The compositions also typically comprise an initiator system, preferably a photoinitator system containing at least 0.08 wt-% of one or more photosensitizers.

  本发明涉及一种可硬化的牙科组合物，其包含：（1）至少一种具有环中至少一个硫原子的环状烯丙基化合物，以及（2）至少一种乙烯基不饱和化合物，例如取代的（甲基）丙烯酰基化合物。该组合物通常还包括引发剂体系，优选为至少含有0.08重量％的一个或多个光敏剂的光引发剂体系。
• Porphyrin Derivatives and Their Use in Photodynamic Therapy
  申请人：Love William

  公开号：US20070281915A1

  公开（公告）日：2007-12-06

  A compound of formula I: wherein X 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , Y 3 , Y 4 and Z have meanings given in the description, and metallated forms of such compounds, which are useful in the treatment of medical conditions for which a photodynamic compound is indicated. Pharmaceutical formulations and methods of treatment of a medical condition for which a photodynamic agent is indicated are also disclosed. Sterilising solutions comprising a compound of the invention, and the use thereof, are also disclosed.

  公式I的化合物：其中X1，X2，X3，X4，Y1，Y2，Y3，Y4和Z具有描述中给出的含义，以及这些化合物的金属化形式，可用于治疗需要光动力化合物的医疗状况。还公开了制药配方和治疗光动力剂适用的医疗状况的方法。还公开了包含发明化合物的灭菌溶液及其用途。
• PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY
  申请人：SHIONOGI & CO., LTD.

  公开号：EP0848004A1

  公开（公告）日：1998-06-17

  A compound of the formula I: or a pharmaceutically acceptable salt or a hydrate thereof, which has the activity of inhibiting the production of prostaglandin E2 by inhibiting cytosolic phospholipase2.

  一种式 I.化合物或其药学上可接受的盐或水合物，具有通过抑制细胞磷脂酶 2 来抑制前列腺素 E2 生成的活性： 或其药学上可接受的盐或水合物，具有通过抑制细胞膜磷脂酶 2 来抑制前列腺素 E2 生成的活性。